LifeWatch Receives CE Mark for Its LifeWatch V Health Smart Phone  
12/7/2012 9:26:08 AM

Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE), the leading wireless remote cardiac and medical patient monitoring service provider in the U.S., today reports that its LifeWatch V health smartphone platform was awarded the CE Mark (Number 2074225CE02). The CE Mark allows LifeWatch AG to launch its new LifeWatch V in Europe.

A CE mark confirms that the LifeWatch V system has met the applicable directives of the European Commission (EC) and as such, can be marketed to the 30-nation EEA and Switzerland. The LifeWatch V is a fully featured state-of-the-art smartphone that allows patients and health- and wellbeing-conscious consumers to self-operate a wide range of embedded medical sensors, wellness-related applications, cloud-based services and 24/7 call center support.

By using the barely visible sensors on the phone's frame, patients and health- and wellness consumers can track, capture, collect and analyze their health measurements anywhere anytime. The sensors include ECG, body temperature, blood glucose, heart rate, blood oxygen saturation, body fat percentage and stress analysis measurement. All of the collected data can be retrieved from the cloud for a follow-up. Users can take corrective action, plan diets and activities, securely share the information with a health provider or family member, trend and analyze the data and more. Patients may also program the LifeWatch V to remind them of their drug type, dose and intake time.

The LifeWatch V handset unit includes a service enablement platform to support the transmission of medical data to be analyzed, evaluated and communicated to health professionals and call center personnel around the clock. The device wirelessly interacts with a cloud-based environment allowing its' users direct access to a wide range of complementary medical and wellness related services.

The LifeWatch V smartphone is an important milestone on the Company's way towards more diversification into new service areas such as the consumer and wellness markets and into new geographies.

"This is the first time in the company's history that a multi-parameter device with five medical functions has been awarded the CE Mark", stated Dr. Yacov Geva, Chairman of LifeWatch AG. "The approval demonstrates our capacity to develop and manufacture devices that meet commercial regulatory requirements not only in the U.S. but also in Europe and elsewhere".

LifeWatch is currently in discussions with a number of multi-national cell carriers, pharmaceutical and healthcare providers all over the world on partnership opportunities of the LifeWatch V.

About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare technology and solution company, specializing in advanced telehealth systems and wireless remote patient monitoring services. LifeWatch services cater to individuals, ranging from high-risk and chronically ill patients, to consumers of health and wellness products. LifeWatch AG has operative subsidiaries in the United States, in Switzerland and in Israel and is the parent company of LifeWatch Services Inc., and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a leading US-based provider of cardiac monitoring services and home sleep testing of Obstructive Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel, is a leading developer and manufacturer of telemedicine products. The Company is planning to introduce the LifeWatch V, an Android-based smartphone with medical sensors and apps that uses a cloud-based service platform. For additional information, please visit {}[HYPERLINK:].

Sign-up for customized email alerts and documentation requests is available at

This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding future results of operations and financial position, business strategy and plans and objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. LifeWatch AG has based these forward-looking statements largely on current expectations and projections about future events and financial trends that it believes may affect the financial condition, results of operations, business strategy, short term and long term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. All forward-looking statements are based only on data available to LifeWatch AG at the time of the issue of this press release. LifeWatch AG does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.